Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse M Cedarbaum

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Journal of Parkinson'S Disease|November 8, 2018
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-SynucleinKalpana M Merchant, Jesse M Cedarbaum, Patrik Brundin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 19, 2019
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054Miroslaw Brys, Laura Fanning, Serena Hung, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 22, 2022
Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or SeverityNurit Omer, Nir Giladi, Tanya Gurevich, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 22, 2021
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or SeverityNurit Omer, Nir Giladi, Tanya Gurevich, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trialsMichael Gold, Joan Amatniek, Maria C Carrillo, et al.
Journal of Parkinson'S Disease|February 20, 2025
The effect of polygenic risk score on PD risk and phenotype in <i>LRRK2</i> G2019S and <i>GBA1</i> carriersOrly Goldstein, Shachar Shani, Mali Gana-Weisz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2011
Revision of the criteria for Alzheimer’s disease: A symposiumSteven T DeKosky, Maria C Carrillo, Creighton Phelps, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2015
Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)Enchi Liu, Johan Luthman, Jesse M Cedarbaum, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2020
Tossing and Turning in Bed: Nocturnal Movements in Parkinson's DiseaseAnat Mirelman, Inbar Hillel, Lynn Rochester, et al.
Neurology|February 5, 2024
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical TrialR Matthew Hutchison, Kyle Fraser, Minhua Yang, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Journal of Parkinson'S Disease|November 8, 2018
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-SynucleinKalpana M Merchant, Jesse M Cedarbaum, Patrik Brundin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|June 19, 2019
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054Miroslaw Brys, Laura Fanning, Serena Hung, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 22, 2022
Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or SeverityNurit Omer, Nir Giladi, Tanya Gurevich, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 22, 2021
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or SeverityNurit Omer, Nir Giladi, Tanya Gurevich, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trialsMichael Gold, Joan Amatniek, Maria C Carrillo, et al.
Journal of Parkinson'S Disease|February 20, 2025
The effect of polygenic risk score on PD risk and phenotype in <i>LRRK2</i> G2019S and <i>GBA1</i> carriersOrly Goldstein, Shachar Shani, Mali Gana-Weisz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 17, 2011
Revision of the criteria for Alzheimer’s disease: A symposiumSteven T DeKosky, Maria C Carrillo, Creighton Phelps, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2015
Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)Enchi Liu, Johan Luthman, Jesse M Cedarbaum, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2020
Tossing and Turning in Bed: Nocturnal Movements in Parkinson's DiseaseAnat Mirelman, Inbar Hillel, Lynn Rochester, et al.
Neurology|February 5, 2024
Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical TrialR Matthew Hutchison, Kyle Fraser, Minhua Yang, et al.
Pageof 8